Business Wire

NTHU’s Boron Neutron Capture Therapy Center Begins Treating Overseas Brain Cancer Patients

Share

On February 14th the melodious strains of the fourth movement of Mahler's Fifth Symphony were heard inside the building of Tsing Hua Open pool Reactor (THOR) at National Tsing Hua University (NTHU) - for this is the favorite piece of music of a European woman who was here to undergo Boron Neutron Capture Therapy (BNCT) for a malignant brain tumor. This was her second course of treatment. The size of malignant glioma deep in her brainstem was reduced from 3.51 cm to 1.06 cm after the first treatment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200325005023/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The BNCT treatment mechanism. Since being converted for use in BNCT, the research reactor at NTHU has been used to treat over 130 patients. (Graphic: National Tsing Hua University)

In cooperation with the Taipei Veterans General Hospital (TVGH), NTHU has converted THOR for use in BNCT. To date, the treatment has provided a new lease on life to over 130 cancer patients from around the world.

According to Professor Chou Fong-in, BNCT is a target radiation therapy in which the patient is first injected with a boron-containing drug; once the drug has accumulated in the tumor, the neutron beam is used to irradiate the tumor for delivering curative doses specifically to tumors, while sparing normal tissue.

As explained by TVGH oncologist Chen Yi-wei, boron-10 drug contains the structure like essential amino acids, and cancer cells need lots of nutrients to support their abnormal proliferation. Thus cancerous cells absorb almost all the boron-10 before the normal cells have a chance to. The boron acts as a kind of explosive charge, and once the cancerous cells have got their fill of it, the neutron beam is used to “detonate” the charge, killing off the cancer cells.

The husband of the patient is a physician. He said that his wife used to be an avid tennis player, but four years ago she unexpectedly saw two balls flying towards her at the same time, a classic symptom of diplopia. A computerized tomography (CT) scan, however, later revealed a lesion of glioma in her brain, located deep inside her brainstem. After undergoing two craniotomies with gamma knife radiotherapy, the glioma relapsed and had turned malignant. On the advice of an expert of Radiation Oncology, they inquired about the treatment being offered at the TVGH.

According to Dr. Chen, the key requirements for BNCT are a boron-containing drug suitable for absorption by cancer cells, and a stable neutron source with appropriate energy spectrum. NTHU’s research reactor has been retrofitted to provide the neutron source. It is even better than the accelerator driven neutron source developed in Japan for use in hospitals.

NTHU and the Taoyuan City Government are planning to jointly develop a medical complex as part of the Taoyuan Aerotropolis to be built near the Taoyuan Airport. The BNCT will play a major role at the new facility, and will be used to treat both Taiwanese and overseas patients.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Holly Hsueh
TEL: (886)3-5162006
e-mail: hoyu@mx.nthu.edu.tw

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye